Compare Gujarat Kidney with Similar Stocks
Dashboard
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 1.08 times
Healthy long term growth as Net Sales has grown by an annual rate of 0% and Operating profit at 0%
With a growth in Net Sales of 2.87%, the company declared Very Positive results in Mar 26
With ROE of 6.1, it has a Very Expensive valuation with a 4.1 Price to Book Value
Total Returns (Price + Dividend) 
Gujarat Kidney for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Gujarat Kidney & Super Speciality Ltd Sees Technical Momentum Shift Amid Mixed Market Signals
Gujarat Kidney & Super Speciality Ltd, a micro-cap player in the hospital sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. Despite a recent 1.6% decline in the stock price to ₹135.35, the company’s year-to-date return of 31.7% significantly outpaces the Sensex’s negative 12.9%, signalling underlying strength amid short-term technical caution.
Read full news article
Gujarat Kidney & Super Speciality Ltd Quality Parameters Upgrade: A Detailed Fundamental Analysis
Gujarat Kidney & Super Speciality Ltd, a micro-cap player in the hospital sector, has recently seen its quality grade upgraded from "Does Not Qualify" to "Average" by MarketsMOJO. This shift reflects notable improvements in key business fundamentals such as return on capital employed (ROCE), debt management, and operational efficiency. However, certain areas remain under scrutiny as the company navigates a competitive healthcare landscape. This article delves into the detailed financial metrics and quality parameters that underpin this upgrade, providing investors with a comprehensive view of the company’s evolving fundamentals.
Read full news article
Gujarat Kidney & Super Speciality Ltd is Rated Hold
Gujarat Kidney & Super Speciality Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 30 May 2026, providing investors with the latest insights into its performance and outlook.
Read full news article Announcements 
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 2 Schemes (0.0%)
Held by 12 FIIs (4.88%)
Pragnesh Yashwantsinh Bharpoda (38.16%)
Khandelwal Finance Private Limited (1.67%)
10.64%
Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ
QoQ Growth in quarter ended Mar 2026 is -5.33% vs 1.24% in Dec 2025
QoQ Growth in quarter ended Mar 2026 is -41.20% vs 1.30% in Dec 2025
Half Yearly Results Snapshot (Standalone) - Sep'25
Not Applicable: The company has declared_date for only one period
Not Applicable: The company has declared_date for only one period
Nine Monthly Results Snapshot (Standalone) - Dec'25
Not Applicable: The company has declared_date for only one period
Not Applicable: The company has declared_date for only one period
Annual Results Snapshot (Standalone) - Mar'26
Not Applicable: The company has declared_date for only one period
Not Applicable: The company has declared_date for only one period






